Related Experiment Videos
Association between orosomucoid types and cancer
C Fan1, U Stendahl, N Stjernberg
1Department of Medical Genetics, Umeå University, Sweden.
Oncology
|November 1, 1995
Summary
The Orosomucoid 1*2 (ORM1*2) variant, associated with immunosuppression, is more frequent in cancer patients. This suggests the ORM1*2 type may promote cancer progression by aiding tumor immune escape.
Area of Science:
- Immunogenetics
- Oncology
- Biochemistry
Background:
- Orosomucoid (ORM) is an acute-phase protein with known immunosuppressive effects.
- Previous research suggests ORM may contribute to tumor immune escape by acting as a blocking factor.
Purpose of the Study:
- To investigate the association between Orosomucoid (ORM) phenotypes and various carcinoma types.
- To determine if specific ORM variants influence cancer progression and immune evasion.
Main Methods:
- Isoelectric focusing and immunoprinting were used to analyze ORM types.
- Frequencies of ORM alleles and phenotypes were compared between cancer patients and population controls.
Main Results:
- Significantly increased frequencies of the ORM1*2 allele and ORM1 2 phenotype were observed in patients with breast, lung, ovarian, and endometrial carcinomas.
- The ORM1*2 variant showed a relative risk of 1.56 for carcinoma development.
Conclusions:
- The ORM1*2 variant may play a role in cancer progression, potentially due to enhanced immunosuppressive properties.
- These findings suggest a link between specific Orosomucoid genetic variants and increased cancer risk.